Modality
ADC
MOA
TROP-2 ADC
Target
GPRC5D
Pathway
Lipid Met
Heart Failure
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
Dec 2017
→ Jul 2027
Phase 1Current
NCT06929956
106 pts·Heart Failure
2017-12→TBD·Active
NCT06459103
1,963 pts·Heart Failure
2023-09→2027-07·Recruiting
2,069 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-136mo awayFast Track· Heart Failure
2027-07-011.3y awayPh2 Data· Heart Failure
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1/2
Active
P1/2
Recruit…
Catalysts
Fast Track
2026-10-13 · 6mo away
Heart Failure
Ph2 Data
2027-07-01 · 1.3y away
Heart Failure
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06929956 | Phase 1/2 | Heart Failure | Active | 106 | ORR |
| NCT06459103 | Phase 1/2 | Heart Failure | Recruiting | 1963 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| GMA-5010 | Genmab | Phase 3 | JAK2 |